Effect of Chronic Treatment of Adult Spontaneously Hypertensive Rats With an Endothelin Receptor Antagonist
- 1 April 1995
- journal article
- research article
- Published by Wolters Kluwer Health in Hypertension
- Vol. 25 (4), 495-500
- https://doi.org/10.1161/01.hyp.25.4.495
Abstract
Abstract We previously showed that endothelin-1 expression was increased in vascular endothelium of deoxycorticosterone acetate–salt hypertensive rats, whereas in spontaneously hypertensive rats (SHR) it is similar to or less than that in normotensive rats. Treatment with the combined endothelin type A/endothelin type B receptor antagonist bosentan moderately reduced blood pressure rise and nearly completely blunted the development of vascular hypertrophy, particularly in small arteries, in the deoxycorticosterone acetate–salt hypertensive model, suggesting a paracrine role for vascular endothelin-1 in the induction of blood vessel hypertrophy in some forms of experimental hypertension. In the present study we examined the effect of chronic oral treatment for 4 weeks of 12-week-old SHR and Wistar-Kyoto rats (WKY) with 100 mg/kg per day bosentan. Blood pressure rose to hypertensive levels similarly in bosentan-treated and untreated SHR; systolic pressure of WKY was also unaffected. The wet weights of the heart, of aortic segments, and of the mesenteric arterial bed were similar in treated and untreated SHR. When coronary, renal arcuate, mesenteric, and femoral small arteries were evaluated on a wire myograph, the media width and media-to-lumen ratio were greater and the lumen diameter was smaller in vessels from SHR relative to those from WKY, except in small arteries from the renal cortex, in which the lumen was not significantly different in both strains. The media cross-sectional area of small arteries from the four vascular beds was similar in both strains. Identical morphometric parameters were found in the four vascular beds in bosentan-treated and untreated rats of each strain. We conclude that endothelins do not play a role in the maintenance of elevated blood pressure or in vascular hypertrophy or remodeling in adult SHR. This study also showed similar morphometric changes consistent with remodeling in small arteries of the coronary, mesenteric, and femoral vascular beds of SHR, whereas the changes in renal cortical small arteries were consistent with vascular hypertrophy.Keywords
This publication has 16 references indexed in Scilit:
- Increased expression of endothelin-1 gene in blood vessels of deoxycorticosterone acetate-salt hypertensive rats.Hypertension, 1993
- Increased endothelin-1 content in blood vessels of deoxycorticosterone acetate-salt hypertensive but not in spontaneously hypertensive rats.Hypertension, 1993
- Molecular and cellular biology of endothelin and its receptors???Part IIJournal Of Hypertension, 1993
- ETB receptors on aortic smooth muscle cells of spontaneously hypertensive ratsAmerican Journal of Physiology-Cell Physiology, 1993
- Calcium, phosphoinositide, and 1,2-diacylglycerol responses of blood vessels of deoxycorticosterone acetate-salt hypertensive rats to endothelin-1.Hypertension, 1992
- Endothelin vascular receptors and responses in deoxycorticosterone acetate-salt hypertensive rats.Hypertension, 1992
- Growth factor activity of endothelin on vascular smooth muscleAmerican Journal of Physiology-Cell Physiology, 1990
- Endothelin is a potent mitogen for rat vascular smooth muscle cellsAtherosclerosis, 1989
- Pressor effects of circulating endothelin are limited by its removal in the pulmonary circulation and by the release of prostacyclin and endothelium-derived relaxing factor.Proceedings of the National Academy of Sciences, 1988
- A novel potent vasoconstrictor peptide produced by vascular endothelial cellsNature, 1988